Mission Therapeutics reaching the second major milestone in it’s collaboration with AbbVie Inc, has been featured in a recent MedNous article (14 August 2021). To read about this achievement and to hear from our CEO and CBO, click here

---

We were delighted to be named as one of the Top 15 Biotech companies ‘Shaking up the Scene in Cambridge’, in the December 2020 Labiotech.eu article. Read more

---

Mission Therapeutics recently featured in BioMed Realty’s virtual Grand Opening of the Glenn Berge Building located on Babraham Research Campus (October 2020). Click here to watch the event again and for a tour of our new office and labs.

---

Mission Therapeutics’ collaboration with AbbVie has been featured in the DDNews article – ‘Collaboration “DUBbed” a success‘ (January 2020). Read more

---

News of Mission Therapeutics move to the new BioMed Realty facilities, on Babraham Research Campus in 2020, is featured in Business Weekly and Cambridge Network

---

Mission Therapeutics is listed in Business Weekly’s ‘Killer50’, which recognises the top disruptive life sciences and technology companies in Cambridge and the East of England, May 2018. Read more

---

Read our article ‘Mitochondrial quality control as potential therapy’, by Paul Thompson, VP Clinical Development, Mission Therapeutics, featured in the March 2018 edition of MedNous, published by Evernow Publishing Ltd.

---

Interview with Mission Therapeutics’ CEO, Anker Lundemose, at BIO-Europe (November 2017). Click here

---

Mission Therapeutics is featured in the Business Weekly article – ‘Mission becomes possible for new medical discoveries’, 6 October 2017. Read more

---

Mission Therapeutics is featured in the Labiotech article – ‘New Grant to Advance a Whole New Treatment Against Parkinson’s in the UK’, 11 April 2017. Read more

---

Interview with Mission Therapeutics’ CEO, Anker Lundemose, with Pharma TV (December 2016).

---

Mission Therapeutics has been listed as one of the 15 best Biotechs in Cambridge by LaBiotech. Read more

---

Interview with Mission Therapeutics’ CEO, Anker Lundemose, on Edison TV (November 2016).

---

Mission Therapeutics’ CEO, Anker Lundemose, has been listed as one the 13 Biotech Leaders you should know in the Golden Triangle by LaBiotech. Read more

---

Mission Therapeutics’ Chief Medical Officer, Dr Michael Koslowski, has been listed as one of the 20 top translational researchers of 2015, in Nature Biotechnology.

---

Mission Therapeutics is featured in the recent Pharmaphorum article, “Will the UK ever produce a world-class biotech company?”, 28 July 2016.

---

Mission Therapeutics’ CEO, Anker Lundemose features in BIA’s new report, “Money, momentum and maturity: UK biotech financing and deals in 2015/16”, showing that UK biotech venture capital hit record high in 2015 with £489m raised.

---

Mission Therapeutics shortlisted in the ‘Emerging Star’ Award category as part of the 15th Annual European Mediscience Awards. The ceremony will be held at the European Mediscience awards dinner on Thursday 9 June 2016. Read more

---

Mission Therapeutics is delighted that its CSO and Founding scientist, Professor Steve Jackson, has won the 2016 Dr A.H. Heineken Prize for Medicine. Read more

---

Professor Jackson’s achievement was also recently reported in the Business Weekly. To read the article in full, please follow this link

---

Mission Therapeutics and Professor Steve Jackson featured in Nature Reviews Drug Discovery article, ‘Drug developers delve into the cell’s trash-disposal machinery’, 3rd May 2016. Read more

---

In a recent a EP Vantage article on venture financing, Mission Therapeutics was featured as having ‘seized the global top spot for the largest round of the quarter’. Read more

---

Mission Therapeutics announced as being top of the list of EU Biotech VC Financings, 1Q 2016, in the recent SCRIP article – ‘UK Firms Lead As EU Biotechs Complete Best Ever 1Q VC Fundraising’. Read more

---

Mission Therapeutics is delighted that its CSO and Founding scientist, Professor Steve Jackson, has been honoured with the prestigious King Faisal International Prize for Science. Read more

---

Professor Jackson’s achievement was also recently reported in the Business Weekly. To read the article in full, please follow this link

---

Mission Therapeutics’ CEO, Anker Lundemose was recently interviewed by Philip Hemme, co-founder of LaBiotech, at Sachs 9th Annual European Life Science CEO forum and exhibition in Zurich. To view the video, please visit the LaBiotech website

---

Interview with Mission Therapeutics’ CEO, Anker Lundemose, in PharmaTimes (March 2016). To read the Smart People article in full, please follow this link (pg.40)

---

Interview with Mission Therapeutics’ CEO, Anker Lundemose, on Cambridge TV (January 2016).

---

Interview with Mission Therapeutics’ VP of Scientific Affairs, Xavier Jacq, in Biotech Finances (October 2015). To read the article in full please follow this link

---

Interview with CEO of Mission Therapeutics, Anker Lundemose and Imperial Innovations (July 2015)